AVIR
Atea Pharmaceuticals Inc
5.20$
-2.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
Atea Pharmaceuticals Inc (AVIR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -37 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.0 | -2.0 | -2.0 | -3.2 | -3.3 | -1.9 | -3.7 | -3.9 | -4.5 | -7.8 | -9.5 | 319 | -17 | -17 | 23 | -75 | -59 | -19 | -21 | -22 | -30 | -16 | -18 | -22 | -40 | -42 | -23 | -30 | -31 | -33 | -40 | -28 | -46 | -37 | -152 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.4 | |
| – | – | – | – | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 4.2 | 2.8 | 7.3 | 10 | 11 | 11 | 12 | 12 | 12 | 12 | 13 | 12 | 12 | 12 | 13 | 13 | 12 | 14 | 7.0 | 4.7 | 4.5 | 4.6 | 3.7 | 3.4 | 16 | |
| – | – | – | – | – | – | 0.2 | – | 0.2 | 0.2 | 4.2 | 2.8 | 7.3 | 10 | 11 | 11 | 12 | 12 | 12 | 8.6 | 13 | 12 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.2 | – | – | 19 | -1.2 | 1.1 | -0.2 | 0.5 | -0.7 | 2.0 | 3.9 | 295 | -55 | -29 | 40 | -204 | -29 | 0.2 | -22 | 4.1 | -3.9 | 3.3 | 7.4 | 9.4 | 14 | -11 | -1.6 | -8.5 | -1.6 | 0.8 | -1.9 | 19 | -4.2 | -7.1 | 6.0 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.9 | 0.0 | 1.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| – | – | – | – | – | – | 0.0 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.9 | -487 | 33 | 24 | 47 | -59 | 28 | 57 | 125 | -122 | -3.4 | 86 | 15 | 41 | 47 | 30 | 34 | 152 | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.5 | 0.1 | 0.8 | 0.1 | 0.2 | – | 0.1 | – | 0.2 | – | – | – | – | – | 0.0 | – | -0.5 | -14 | -11 | 26 | 0.1 | 0.7 | 15 | |
| – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 106 | -0.9 | 426 | 0.5 | 0.1 | 0.8 | 0.1 | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 | 0.0 | 0.1 | 0.0 | 0.2 | 0.0 | 0.1 | 0.0 | -0.3 | -14 | -11 | 0.0 | 0.3 | 0.0 | -11 | |
| 4.9 | 4.9 | 4.9 | -3.2 | -3.3 | -1.9 | -3.7 | 22 | -4.5 | 99 | -10 | 745 | -16 | -17 | 23 | -75 | -59 | -21 | -508 | 12 | -5.2 | 30 | -76 | 5.9 | 17 | 82 | -145 | -34 | 55 | -32 | -10 | 18 | -16 | -2.8 | -11 | |
| -2.0 | -2.0 | -2.0 | -3.2 | -3.3 | -1.9 | -3.7 | -3.9 | -4.5 | -7.8 | -9.5 | 319 | -17 | -17 | 23 | -75 | -59 | -21 | -21 | -22 | -30 | -16 | -18 | -22 | -40 | -42 | -23 | -30 | -31 | -33 | -40 | -28 | -46 | -37 | -152 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.